Skip to main content

Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma

Abstract

Background

Immunity plays an important role in CNS-DLBCL development. CNS-DLBCL predictive factors need to be improved.

Objective

To evaluate the predictive value of circulating lymphocyte subsets in PCNSL patients.

Methods

We prospectively analyzed blood lymphocyte immunophenotyping (LIP) in newly CNS-DLBCL referred to our institution between December 2013 and January 2020. LIP analysis was performed before rituximab and chemotherapy administration. The clinical, radiological, histological, biological and treatment data were retrospectively collected.

Results

Fifty-three patients were included with a median age of 69.7 (range 21.7–87.5). Median KPS was 60 (range 30–100). Thirty-three patients (64%) presented with one or several lymphopenias: 21 (40%), 24 (46%) and 9 (17%) NK, T and B lymphopenias respectively. Only 11 patients (21%) had normal LIP. Median CD4+/CD8+ ratio was 2.11 (range 0.54–9.11). This ratio was normal, low or high in 27%, 28% and 44% of patients respectively. The presence of steroids did not impact LIP results. Complete, partial responses, stable and progressive disease (PD) were observed in 24 (50%), 10 (21%), 4 (8%), and 10 (21%) patients respectively. CD4+/CD8+ ratio tended to be different between refractory (PD patients) and non-refractory patients (p = 0.077, ROC AUC: 0.684). Median progression-free survival (PFS) and overall survival (OS) were 14.7 (95%CI 6.5–22.9) and 43.2 (95%CI 21.6–64.9) months, respectively. In multivariate analyses, adjusted by KPS, a CD4+/CD8+ ratio > 1.97 was associated with poor PFS [p = 0.043, HR = 3.32 (1.02–4.88)] and tended to be associated with worse OS (p = 0.064).

Conclusion

LIP at baseline may predict refractory disease and exhibits a prognostic value in CNS-DLBCL patients.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

Data availability

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request. The study was approved by our local ethics committee in accordance with the Declaration of Helsinki.

References

  1. Grommes C, Rubenstein JL, DeAngelis LM et al (2019) Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol 21:296–305. https://doi.org/10.1093/neuonc/noy192

    Article  PubMed  Google Scholar 

  2. Grommes C, DeAngelis LM (2017) Primary CNS lymphoma. J Clin Oncol 35:2410–2418. https://doi.org/10.1200/JCO.2017.72.7602

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Omuro AMP, Taillandier L, Chinot O et al (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85:207–211. https://doi.org/10.1007/s11060-007-9397-0

    CAS  Article  PubMed  Google Scholar 

  4. Houillier C, Soussain C, Ghesquières H et al (2020) Management and outcome of primary CNS lymphoma in the modern era: an LOC network study. Neurology 94:e1027–e1039. https://doi.org/10.1212/WNL.0000000000008900

    Article  PubMed  PubMed Central  Google Scholar 

  5. Houillier C, Taillandier L, Dureau S et al (2019) Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS randomized phase II PRECIS study. J Clin Oncol 37:823–833. https://doi.org/10.1200/JCO.18.00306

    CAS  Article  PubMed  Google Scholar 

  6. Ghesquieres H, Chevrier M, Laadhari M et al (2019) Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective “proof of concept” phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†. Ann Oncol 30:621–628. https://doi.org/10.1093/annonc/mdz032

    CAS  Article  PubMed  Google Scholar 

  7. Soussain C, Choquet S, Blonski M et al (2019) Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: Final analysis of the phase II “proof-of-concept” iLOC study by the Lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network. Eur J Cancer 117:121–130. https://doi.org/10.1016/j.ejca.2019.05.024

    CAS  Article  PubMed  Google Scholar 

  8. Marcelis L, Antoranz A, Delsupehe A-M et al (2020) In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy. Cancer Immunol Immunother 69:1751–1766. https://doi.org/10.1007/s00262-020-02575-y

    CAS  Article  PubMed  Google Scholar 

  9. Ferreri AJM, Blay J-Y, Reni M et al (2003) Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 21:266–272. https://doi.org/10.1200/JCO.2003.09.139

    Article  PubMed  Google Scholar 

  10. Abrey LE, Ben-Porat L, Panageas KS et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5715. https://doi.org/10.1200/JCO.2006.08.2941

    Article  PubMed  Google Scholar 

  11. Schorb E, Kasenda B, Atta J et al (2013) Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 98:765–770. https://doi.org/10.3324/haematol.2012.076075

    Article  PubMed  PubMed Central  Google Scholar 

  12. Liu C-J, Lin S-Y, Yang C-F et al (2020) A new prognostic score for disease progression and mortality in patients with newly diagnosed primary CNS lymphoma. Cancer Med 9:2134–2145. https://doi.org/10.1002/cam4.2872

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  13. Lu Y, Yu J, Gong W et al (2021) An Immune-Clinical Prognostic Index (ICPI) for patients with de novo follicular lymphoma treated With R-CHOP/CHOP chemotherapy. Front Oncol 11:708784. https://doi.org/10.3389/fonc.2021.708784

    Article  PubMed  PubMed Central  Google Scholar 

  14. Gu Y, Jin Y, Ding J et al (2020) Low absolute CD4+ T cell counts in peripheral blood predict poor prognosis in patients with newly diagnosed multiple myeloma. Leuk Lymphoma 61:1869–1876. https://doi.org/10.1080/10428194.2020.1751840

    CAS  Article  PubMed  Google Scholar 

  15. Cao X, Kong Y-L, Wang L et al (2021) Circulating low CD4+/CD8+ ratio is associated with poor prognosis in Waldenstrom macroglobulinemia patients. Ann Hematol 100:995–1002. https://doi.org/10.1007/s00277-021-04474-3

    CAS  Article  PubMed  Google Scholar 

  16. Zhang X-Y, Xu J, Zhu H-Y et al (2016) Negative prognostic impact of low absolute CD4+ T cell counts in peripheral blood in mantle cell lymphoma. Cancer Sci 107:1471–1476. https://doi.org/10.1111/cas.13020

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  17. An Y, Jiang W, Andraos TY et al (2019) Multi-institutional Investigation: circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. Radiother Oncol 131:88–92. https://doi.org/10.1016/j.radonc.2018.12.003

    Article  PubMed  Google Scholar 

  18. Luo Q, Yang C, Fu C et al (2021) Prognostic role of blood markers in primary central nervous system lymphoma patients treated with high-dose methotrexate-based therapy. Front Oncol 11:639644. https://doi.org/10.3389/fonc.2021.639644

    Article  PubMed  PubMed Central  Google Scholar 

  19. Jung J, Lee H, Yun T et al (2017) Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary. Oncotarget 8:74975–74986. https://doi.org/10.18632/oncotarget.20480

    Article  PubMed  PubMed Central  Google Scholar 

  20. Wang J, Zhou X, Liu Y et al (2017) Prognostic significance of neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma: a meta-analysis. PLoS ONE 12:e0176008. https://doi.org/10.1371/journal.pone.0176008

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Le M, Garcilazo Y, Ibáñez-Juliá M-J et al (2019) Pretreatment hemoglobin as an independent prognostic factor in primary central nervous system lymphomas. Oncologist 24:e898–e904. https://doi.org/10.1634/theoncologist.2018-0629

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank the AP-HM Tumor Bank (Authorization Number: AC2018-31053; CRB BB-0033-00097) for providing tissue samples. We thank the ARTC-Sud patients’s association. We thank the Cancéropôle PACA.

Funding

This work was supported by the patient’s association ARTC-Sud.

Author information

Authors and Affiliations

Authors

Contributions

ET: Conceptualization; AB, CB, VH, GP, CC, MB, RA and OC: data curation; AB, OC, ET: formal analysis; ET: methodology; OC, ET: supervision; AB, ET: writing—original draft; All authors: writing—review and editing.

Corresponding author

Correspondence to Emeline Tabouret.

Ethics declarations

Conflict of interest

The authors have no relevant financial or non-financial interests to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 16 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Berthelot, A., Bequet, C., Harlay, V. et al. Prognostic value of circulating lymphocyte subsets in primary central nervous system lymphoma. J Neurooncol 159, 15–22 (2022). https://doi.org/10.1007/s11060-022-04032-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-022-04032-5

Keywords

  • CNS-DLBCL
  • Lymphocytes
  • Lymphocyte immunophenotyping
  • CD4/CD8 + ratio